Full Breakdown
U.S. Dementia Economic Burden Projected at $818 Billion in 2026
6/25/2026, 12:47:02 AM
2026 Dementia Cost Estimate: $818 Billion
A University of Southern California Schaeffer Center study, published in Alzheimer’s & Dementia, estimates U.S. dementia costs at $818 billion in 2026. It covers 5.7 million Americans with dementia (5.1 million aged 65 +), combining medical, long-term, quality-of-life, unpaid-care and earnings-loss components.
Methodology and Research Team
The analysis is part of the U.S. Cost of Dementia Project, funded by a National Institute on Aging cooperative agreement. Researchers applied dynamic microsimulation to the Health and Retirement Study and Medicare-Medicaid data. Lead investigator Julie Zissimopoulos, principal investigator and Price School professor, oversaw modeling; Dana Goldman, founding director of the USC Schaeffer Institute, provided commentary. Scholars from USC’s Price, Mann, Davis and Viterbi schools, the Alzheimer’s Association and the University of Pennsylvania contributed.
Cost Breakdown
The $818 billion total splits into four categories: patient quality-of-life loss ($320 billion) and caregiver quality-of-life loss ($15 billion); unpaid caregiving valued at $237 billion (5.2 million adults delivering 6.8 billion hours); medical and long-term care ($222 billion), with Medicare/Medicaid covering about 70% ($154 billion) and families paying $46 billion out-of-pocket; and $23 billion in forgone earnings for patients and care partners.
Implications for Policy and Care
Quantifying hidden costs guides resource allocation, assesses new-therapy impact, and supports care-model reforms that keep patients home longer and cut nursing-home demand. Estimates are essential for a dementia population projected to grow substantially.
Official Statements & Responses
Julie Zissimopoulos said the annual, comprehensive estimates help allocate resources for a growing dementia population and that the modeling approach evaluates how disease-slowing treatments could affect quality of life and care demand. Dana Goldman noted that remarkable innovations can alter the disease trajectory if deployed effectively and that the evidence base will give the health-care system clearer insight into future interventions.
Verbatim Quotes
- “By providing annual, comprehensive and transparent estimates of dementia’s total costs, our research can help guide decisions about how to allocate resources as the dementia population is set to grow substantially,” — Julie Zissimopoulos, Lead Researcher, USC Schaeffer Center
- “With our modeling approach, we can ask and answer questions such as: How will a new treatment that slows dementia improve quality of life or affect demand for nursing home care?” — Julie Zissimopoulos, Lead Researcher, USC Schaeffer Center
- “Remarkable innovations can alter the trajectory of dementia in the United States if they are used effectively,” — Dana Goldman, Founding Director, USC Schaeffer Institute
- “The evidence we are building on dementia costs will provide the healthcare system with a clearer understanding of these and future innovations.” — Dana Goldman, Founding Director, USC Schaeffer Institute
What’s Next
The project will update the cost model annually, add new treatment and care data, and publish reports to aid policymakers, providers and researchers addressing the growing economic burden of dementia.
